A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study

H. Ian Robins; Peixin Zhang; Mark R. Gilbert; Arnab Chakravarti; John Frederick de Groot; Sean A. Grimm; Fen Wang; Frank S. Lieberman; Andra Krauze; Andy M. Trotti; Nimish Mohile; Andrew Y J Kee; Howard Colman; Robert Cavaliere; Santosh Kesari; Steven J. Chmura; Minesh Mehta

doi:10.1007/s11060-015-1966-z

A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study

H. Ian Robins
, Peixin Zhang
, Mark R. Gilbert
, Arnab Chakravarti
, John Frederick de Groot
, Sean A. Grimm
, Fen Wang
, Frank S. Lieberman
, Andra Krauze
, Andy M. Trotti
, Nimish Mohile
, Andrew Y J Kee
, Howard Colman
, Robert Cavaliere
, Santosh Kesari
, Steven J. Chmura
, Minesh Mehta

Herbert Wertheim Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of neuro-oncology
Volume	126
DOIs	https://doi.org/10.1007/s11060-015-1966-z
State	Published - Jan 1 2016

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.1007/s11060-015-1966-zLicense: Unspecified

Cite this

Robins, H. I., Zhang, P., Gilbert, M. R., Chakravarti, A., de Groot, J. F., Grimm, S. A., Wang, F., Lieberman, F. S., Krauze, A., Trotti, A. M., Mohile, N., Kee, A. Y. J., Colman, H., Cavaliere, R., Kesari, S., Chmura, S. J., & Mehta, M. (2016). A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. Journal of neuro-oncology, 126. https://doi.org/10.1007/s11060-015-1966-z

Robins, HI, Zhang, P, Gilbert, MR, Chakravarti, A, de Groot, JF, Grimm, SA, Wang, F, Lieberman, FS, Krauze, A, Trotti, AM, Mohile, N, Kee, AYJ, Colman, H, Cavaliere, R, Kesari, S, Chmura, SJ & Mehta, M 2016, 'A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study', Journal of neuro-oncology, vol. 126. https://doi.org/10.1007/s11060-015-1966-z

@article{258aded5ac3648adb6eef20bbe1778c7,

title = "A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study",

author = "Robins, \{H. Ian\} and Peixin Zhang and Gilbert, \{Mark R.\} and Arnab Chakravarti and \{de Groot\}, \{John Frederick\} and Grimm, \{Sean A.\} and Fen Wang and Lieberman, \{Frank S.\} and Andra Krauze and Trotti, \{Andy M.\} and Nimish Mohile and Kee, \{Andrew Y J\} and Howard Colman and Robert Cavaliere and Santosh Kesari and Chmura, \{Steven J.\} and Minesh Mehta",

note = "This study tested the hypothesis that ABT-888 (velparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, can modulate temozolomide (TMZ) resistance in recurrent TMZ refractory glioblastoma patients. The combination regimen (TMZ/ABT-888) was tested using two randomized schedules (5 vs. 21 days), with 6-month progression free survival (PFS6) as the primary endpoint.",

year = "2016",

month = jan,

day = "1",

doi = "10.1007/s11060-015-1966-z",

language = "American English",

volume = "126",

journal = "Journal of neuro-oncology",

}

TY - JOUR

T1 - A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study

AU - Robins, H. Ian

AU - Zhang, Peixin

AU - Gilbert, Mark R.

AU - Chakravarti, Arnab

AU - de Groot, John Frederick

AU - Grimm, Sean A.

AU - Wang, Fen

AU - Lieberman, Frank S.

AU - Krauze, Andra

AU - Trotti, Andy M.

AU - Mohile, Nimish

AU - Kee, Andrew Y J

AU - Colman, Howard

AU - Cavaliere, Robert

AU - Kesari, Santosh

AU - Chmura, Steven J.

AU - Mehta, Minesh

N1 - This study tested the hypothesis that ABT-888 (velparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, can modulate temozolomide (TMZ) resistance in recurrent TMZ refractory glioblastoma patients. The combination regimen (TMZ/ABT-888) was tested using two randomized schedules (5 vs. 21 days), with 6-month progression free survival (PFS6) as the primary endpoint.

PY - 2016/1/1

Y1 - 2016/1/1

UR - https://link.springer.com/content/pdf/10.1007%2Fs11060-015-1966-z.pdf

U2 - 10.1007/s11060-015-1966-z

DO - 10.1007/s11060-015-1966-z

M3 - Article

VL - 126

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

ER -

A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study

Disciplines

Access to Document

Other files and links

Cite this